Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer

Effective adverse event (AE) management is critical to maintaining patients on anticancer therapies. The DECISION trial was a multicenter, randomized, double-blind, placebo-controlled, Phase 3 trial which investigated sorafenib for treatment of progressive, advanced, or metastatic radioactive iodine...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Endocr Relat Cancer
Main Authors: Worden, Francis, Fassnacht, Martin, Shi, Yuankai, Hadjieva, Tatiana, Bonichon, Françoise, Gao, Ming, Fugazzola, Laura, Ando, Yuichi, Hasegawa, Yasuhisa, Park, Do Joon, Shong, Young Kee, Smit, Johannes W A, Chung, John, Kappeler, Christian, Meinhardt, Gerold, Schlumberger, Martin, Brose, Marcia S
Formato: Artigo
Idioma:Inglês
Publicado em: Bioscientifica Ltd 2015
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4570090/
https://ncbi.nlm.nih.gov/pubmed/26370187
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/ERC-15-0252
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados